Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy
The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the lev...
Saved in:
| Main Authors | , , , , , , , |
|---|---|
| Format | Patent |
| Language | English French German |
| Published |
29.07.2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The at least one marker is selected from the group consisting of creatinine, urea, sodium, glucose, HbAlc (glycated hemoglobin), hemoglobin, and hematocrit. Further markers are disclosed. |
|---|---|
| AbstractList | The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The at least one marker is selected from the group consisting of creatinine, urea, sodium, glucose, HbAlc (glycated hemoglobin), hemoglobin, and hematocrit. Further markers are disclosed. |
| Author | WIENHUES-THELEN, URSULA-HENRIKE BLOCK, DIRK MITCHELL, CHERYL SANDERS-VAN WIJK, SANDRA ZAUGG, CHRISTIAN DIETERLE, THOMAS UBBY, JOHAN BRUNNER, HANSPETER |
| Author_xml | – fullname: UBBY, JOHAN – fullname: BLOCK, DIRK – fullname: WIENHUES-THELEN, URSULA-HENRIKE – fullname: SANDERS-VAN WIJK, SANDRA – fullname: ZAUGG, CHRISTIAN – fullname: DIETERLE, THOMAS – fullname: MITCHELL, CHERYL – fullname: BRUNNER, HANSPETER |
| BookMark | eNqNzD1qw1AQBGAVTmEnucNeQIV_AnYZGYWUKdybRR5Zi6V9j91Vgk7ga0eYHCDNDAMfsyoWmhTL4l5JGthuMKc2GZn4jdgd7gM0iPVCYeB4rCGpRDLRK4lSB7aglqUfDZQ5ZDZOP10iQwP5BlVlTBmkHCYzCmkoI4dcQNdxzvm8g3GeXoqnlnvH618_F_RRn46fJXI6wzM3UMS5_trsD4e33e59vf0H-QUMWE5J |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences Physics |
| DocumentTitleAlternate | Biomarqueurs pour l'évaluation du risque et la surveillance thérapeutique chez des patients atteints d'insuffisance cardiaque et traités en fonction de peptide natriurétique de type B Biomarker zur Risikobewertung und Behandlungsüberwachung bei Patienten mit Herzinsuffizienz, die auf Basis des natriuretischen Peptids des Typs B behandelt werden |
| ExternalDocumentID | EP2899544A1 |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_EP2899544A13 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 15:05:51 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English French German |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_EP2899544A13 |
| Notes | Application Number: EP20140152777 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150729&DB=EPODOC&CC=EP&NR=2899544A1 |
| ParticipantIDs | epo_espacenet_EP2899544A1 |
| PublicationCentury | 2000 |
| PublicationDate | 20150729 |
| PublicationDateYYYYMMDD | 2015-07-29 |
| PublicationDate_xml | – month: 07 year: 2015 text: 20150729 day: 29 |
| PublicationDecade | 2010 |
| PublicationYear | 2015 |
| RelatedCompanies | F. HOFFMANN-LA ROCHE AG ROCHE DIAGNOSTICS GMBH |
| RelatedCompanies_xml | – name: F. HOFFMANN-LA ROCHE AG – name: ROCHE DIAGNOSTICS GMBH |
| Score | 2.985157 |
| Snippet | The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING PHYSICS TESTING |
| Title | Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150729&DB=EPODOC&locale=&CC=EP&NR=2899544A1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5Kfd60KtYXc5DegiHdFnsoYh6lCH0gVXoreWw0h25Kk9Cf4N92ZptGL3pZlg0M7ISZnZn95luAeysMe3EQbWHlhoj5kpDicCPu-aaMuPXa537n0bg7fBMv8868BsmuF0bzhG40OSJZVEj2nmt_vfopYrkaW5k9BAktpU-DWd9tldkxRzeUQLt235tO3InTchyatcavfc4rOkI8U6K0x1E00-x77zY3pax-nyiDE9ifkjCVn0JNqgYcObuH1xpwOCrvuxtwoAGaYUaLpRFmZ_BlJ-mSUTXrDCnkREaHo18xbKKvIqzw47jURsvVO0wU8vvVOca0s2ItsSRVzXDzmSK5PkmuD22Dy7KomLu_0D2OuGLoSyTxo6CRhG-ZCM4BB97MGRq0t0Wlx4U3rbTQvoC6SpW8BIzawgwoTQ0jKxBm2PXbXTOKH2NpUWjoi6AJzT_FXP3z7RqO-YdwHdTq3UA9Xxfylg7wPLjTqv8G79GkTw |
| link.rule.ids | 230,309,786,891,25594,76906 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLYmXuMGA8R4-oB2q6i6bLDDhGi7acBeQgPtNvWRQg9rp7XVfgJ_GzvrChe4RFEiWUoiO7bz-QvAjeF5rcD117ByTQT8SEh-uBa0HF36XHrtcL3zYNjsvYnnaWNagnBTC6N4QleKHJE0yiN9T5W9XvwksWyFrUxu3ZCG4ofupG3X8uiYvRsKoG2z3RmP7JFVsyzq1YavbY4rGkI8UqC0fcfkvOw5vZtclLL4faN0D2BnTMKi9BBKMqpA2dp8vFaBvUH-3l2BXQXQ9BIazJUwOYIvM4znjKpZJkguJzI6HJ2CYROdyMcCP45zpbScvcMwQv6_OsWAVpYtJeakqgmuPmMk0yfJ9KGpcVoWI-buz1SNIy4Y-uJL_MioJeFrJoJjwG5nYvU0Wtus2MdZZ1zsQv0EtqI4kqeAfl3oLoWpnm-4QveaTr2p-8F9IA1yDR3hVqH6p5izf-auodybDPqz_tPw5Rz2-XA4J2q0LmArXWbyki7z1L1Sx_ANyQunPA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Biomarkers+for+risk+assessment+and+treatment+monitoring+in+heart+failure+patients+who+receive+B-type+natriuretic+peptide+guided+therapy&rft.inventor=UBBY%2C+JOHAN&rft.inventor=BLOCK%2C+DIRK&rft.inventor=WIENHUES-THELEN%2C+URSULA-HENRIKE&rft.inventor=SANDERS-VAN+WIJK%2C+SANDRA&rft.inventor=ZAUGG%2C+CHRISTIAN&rft.inventor=DIETERLE%2C+THOMAS&rft.inventor=MITCHELL%2C+CHERYL&rft.inventor=BRUNNER%2C+HANSPETER&rft.date=2015-07-29&rft.externalDBID=A1&rft.externalDocID=EP2899544A1 |